Session

Investigator studies in IBD I (Posters)

REAL-WORLD MULTICENTER COMPARISON OF SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY BETWEEN TOFACITINIB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS AFTER FAILURE TO AT LEAST ONE ANTI-TNF AGENT
REAL-WORLD MULTICENTER COMPARISON OF SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY BETWEEN TOFACITINIB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS AFTER FAILURE TO AT LEAST ONE ANTI-TNF AGENT

MODIFIED CRP CUT-OFF IS AS GUIDING AS FCP FOR PREDICTION OF BOTH ENDOSCOPIC AND HISTOLOGIC REMISSIONS IN ULCERATIVE COLITIS PATIENTS
MODIFIED CRP CUT-OFF IS AS GUIDING AS FCP FOR PREDICTION OF BOTH ENDOSCOPIC AND HISTOLOGIC REMISSIONS IN ULCERATIVE COLITIS PATIENTS

MULTIPLE INFLIXIMAB BIOSIMILAR SWITCHES APPEAR TO BE SAFE AND EFFECTIVE IN A REAL-WORLD IBD COHORT
MULTIPLE INFLIXIMAB BIOSIMILAR SWITCHES APPEAR TO BE SAFE AND EFFECTIVE IN A REAL-WORLD IBD COHORT

ON-LINE PSYCHOLOGICAL INTERVENTION IMPROVES DISEASE-RELATED COPING STRATEGIES IN PATIENTS WITH CROHN'S DISEASE
ON-LINE PSYCHOLOGICAL INTERVENTION IMPROVES DISEASE-RELATED COPING STRATEGIES IN PATIENTS WITH CROHN'S DISEASE

CLINICAL AND BIOMARKER REMISSION IS MAINTAINED AFTER SWITCH FROM MONTHLY DOSED VEDOLIZUMAB TO THE NOVEL SUBCUTANEOUS FORMULATION IN INFLAMMATORY BOWEL DISEASE
CLINICAL AND BIOMARKER REMISSION IS MAINTAINED AFTER SWITCH FROM MONTHLY DOSED VEDOLIZUMAB TO THE NOVEL SUBCUTANEOUS FORMULATION IN INFLAMMATORY BOWEL DISEASE

COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL
COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL

USTEKINUMAB IS ASSOCIATED WITH SUPERIOR TREATMENT PERSISTENCE BUT NOT WITH HIGHER REMISSION RATES COMPARED TO VEDOLIZUMAB IN REFRACTORY CROHN’S DISEASE PATIENTS: RESULTS FROM A MULTICENTRE COHORT STUDY
USTEKINUMAB IS ASSOCIATED WITH SUPERIOR TREATMENT PERSISTENCE BUT NOT WITH HIGHER REMISSION RATES COMPARED TO VEDOLIZUMAB IN REFRACTORY CROHN’S DISEASE PATIENTS: RESULTS FROM A MULTICENTRE COHORT STUDY

ORAL FERRIC MALTOL IMPROVES QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND IRON DEFICIENCY ANAEMIA
ORAL FERRIC MALTOL IMPROVES QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND IRON DEFICIENCY ANAEMIA

THE ADDITION OF HIGH-DOSE INTRAVENOUSBOLUS OF METHYL-PREDNISOLONE INCREASES THE EARLY CLINICAL RESPONSE TO ORAL CORTICOSTEROIDS IN MODERATELY ACTIVE ULCERATIVE COLITIS. PRELIMINARY RESULTS OF A PROSPECTIVE, CONTROLLED, MULTICENTRE, RANDOMISED, OPEN-LABEL
THE ADDITION OF HIGH-DOSE INTRAVENOUSBOLUS OF METHYL-PREDNISOLONE INCREASES THE EARLY CLINICAL RESPONSE TO ORAL CORTICOSTEROIDS IN MODERATELY ACTIVE ULCERATIVE COLITIS. PRELIMINARY RESULTS OF A PROSPECTIVE, CONTROLLED, MULTICENTRE, RANDOMISED, OPEN-LABEL

COMPARATIVE DIAGNOSTIC ACCURACY OF MAGNETIC RESONANCE ENTEROGRAPHY WITH INTRAVENOUS GADOLINIUM CONTRAST ENHANCEMENT ORQUANTIFIED SMALL BOWEL MOTILITY INDEX FOR SMALL BOWEL CROHN'S DISEASE ACTIVITY: A MULTI-READER STUDY
COMPARATIVE DIAGNOSTIC ACCURACY OF MAGNETIC RESONANCE ENTEROGRAPHY WITH INTRAVENOUS GADOLINIUM CONTRAST ENHANCEMENT ORQUANTIFIED SMALL BOWEL MOTILITY INDEX FOR SMALL BOWEL CROHN'S DISEASE ACTIVITY: A MULTI-READER STUDY

COMPARATIVE DIAGNOSTIC ACCURACY OF MAGNETIC RESONANCE ENTEROGRAPHY WITH INTRAVENOUS GADOLINIUM CONTRAST ENHANCEMENT ORQUANTIFIED SMALL BOWEL MOTILITY INDEX FOR SMALL BOWEL CROHN'S DISEASE ACTIVITY: A MULTI-READER STUDY
COMPARATIVE DIAGNOSTIC ACCURACY OF MAGNETIC RESONANCE ENTEROGRAPHY WITH INTRAVENOUS GADOLINIUM CONTRAST ENHANCEMENT ORQUANTIFIED SMALL BOWEL MOTILITY INDEX FOR SMALL BOWEL CROHN'S DISEASE ACTIVITY: A MULTI-READER STUDY

Investigator studies in IBD I (Posters)  et al.

THE ADDITION OF HIGH-DOSE INTRAVENOUSBOLUS OF METHYL-PREDNISOLONE INCREASES THE EARLY CLINICAL RESPONSE TO ORAL CORTICOSTEROIDS IN MODERATELY ACTIVE ULCERATIVE COLITIS. PRELIMINARY RESULTS OF A PROSPECTIVE, CONTROLLED, MULTICENTRE, RANDOMISED, OPEN-LABEL
THE ADDITION OF HIGH-DOSE INTRAVENOUSBOLUS OF METHYL-PREDNISOLONE INCREASES THE EARLY CLINICAL RESPONSE TO ORAL CORTICOSTEROIDS IN MODERATELY ACTIVE ULCERATIVE COLITIS. PRELIMINARY RESULTS OF A PROSPECTIVE, CONTROLLED, MULTICENTRE, RANDOMISED, OPEN-LABEL

Investigator studies in IBD I (Posters)  et al.

ORAL FERRIC MALTOL IMPROVES QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND IRON DEFICIENCY ANAEMIA
ORAL FERRIC MALTOL IMPROVES QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND IRON DEFICIENCY ANAEMIA

Investigator studies in IBD I (Posters)  et al.

USTEKINUMAB IS ASSOCIATED WITH SUPERIOR TREATMENT PERSISTENCE BUT NOT WITH HIGHER REMISSION RATES COMPARED TO VEDOLIZUMAB IN REFRACTORY CROHN’S DISEASE PATIENTS: RESULTS FROM A MULTICENTRE COHORT STUDY
USTEKINUMAB IS ASSOCIATED WITH SUPERIOR TREATMENT PERSISTENCE BUT NOT WITH HIGHER REMISSION RATES COMPARED TO VEDOLIZUMAB IN REFRACTORY CROHN’S DISEASE PATIENTS: RESULTS FROM A MULTICENTRE COHORT STUDY

Investigator studies in IBD I (Posters)  et al.

COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL
COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL

Investigator studies in IBD I (Posters)  et al.

CLINICAL AND BIOMARKER REMISSION IS MAINTAINED AFTER SWITCH FROM MONTHLY DOSED VEDOLIZUMAB TO THE NOVEL SUBCUTANEOUS FORMULATION IN INFLAMMATORY BOWEL DISEASE
CLINICAL AND BIOMARKER REMISSION IS MAINTAINED AFTER SWITCH FROM MONTHLY DOSED VEDOLIZUMAB TO THE NOVEL SUBCUTANEOUS FORMULATION IN INFLAMMATORY BOWEL DISEASE

Investigator studies in IBD I (Posters)  et al.

ON-LINE PSYCHOLOGICAL INTERVENTION IMPROVES DISEASE-RELATED COPING STRATEGIES IN PATIENTS WITH CROHN'S DISEASE
ON-LINE PSYCHOLOGICAL INTERVENTION IMPROVES DISEASE-RELATED COPING STRATEGIES IN PATIENTS WITH CROHN'S DISEASE

Investigator studies in IBD I (Posters)  et al.

MULTIPLE INFLIXIMAB BIOSIMILAR SWITCHES APPEAR TO BE SAFE AND EFFECTIVE IN A REAL-WORLD IBD COHORT
MULTIPLE INFLIXIMAB BIOSIMILAR SWITCHES APPEAR TO BE SAFE AND EFFECTIVE IN A REAL-WORLD IBD COHORT

Investigator studies in IBD I (Posters)  et al.

MODIFIED CRP CUT-OFF IS AS GUIDING AS FCP FOR PREDICTION OF BOTH ENDOSCOPIC AND HISTOLOGIC REMISSIONS IN ULCERATIVE COLITIS PATIENTS
MODIFIED CRP CUT-OFF IS AS GUIDING AS FCP FOR PREDICTION OF BOTH ENDOSCOPIC AND HISTOLOGIC REMISSIONS IN ULCERATIVE COLITIS PATIENTS

Investigator studies in IBD I (Posters)  et al.

REAL-WORLD MULTICENTER COMPARISON OF SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY BETWEEN TOFACITINIB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS AFTER FAILURE TO AT LEAST ONE ANTI-TNF AGENT
REAL-WORLD MULTICENTER COMPARISON OF SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY BETWEEN TOFACITINIB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS AFTER FAILURE TO AT LEAST ONE ANTI-TNF AGENT

Investigator studies in IBD I (Posters)  et al.

Item 1 - 20 / 20
1